{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:09:59Z","timestamp":1779304199626,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taiwan Ministry of Health and Welfare Clinical Trial Center","award":["MOHW109-TDU-B-212-114004"],"award-info":[{"award-number":["MOHW109-TDU-B-212-114004"]}]},{"name":"MOST Clinical Trial Consortium for Stroke","award":["MOST 108-2321-B-039-003"],"award-info":[{"award-number":["MOST 108-2321-B-039-003"]}]},{"name":"Tseng-Lien Lin Foundation, Taichung, Taiwan."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare. Thus, we aimed to assess the effect of pioglitazone on primary stroke prevention in Asian patients with type 2 DM without established CV diseases but with risk factors for CV diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between 2000 and 2012, we enrolled patients aged\u2009\u2265\u200918\u00a0years, who were newly diagnosed with type 2 diabetes and had at least one of the following CV risk factors: hypertension and hyperlipidemia. Patients with a history of stroke and those using insulin or glucagon-like peptide-1 agonist for more than 3\u00a0months were excluded. Patients were divided into the pioglitazone and non-pioglitazone groups based on their receipt of pioglitazone during the follow-up period. Propensity-score matching (1:1) was used to balance the distribution of the baseline characteristics and medications. Follow-up was terminated upon ischemic stroke development, withdrawal from the insurance system, or on December 31, 2013, whichever occurred first. The overall incidence of new-onset ischemic stroke in the two groups was subsequently compared. The subgroup analyses of ischemic stroke were conducted using different baseline features. Additionally, the effect of pioglitazone exposure dose on the occurrence of ischemic stroke was evaluated. Chi square test, Student\u2019s\n                      <jats:italic>t<\/jats:italic>\n                      -test, competing risk regression models, Kaplan\u2013Meier method, and log-rank test were some of the statistical tests conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 13 078 patients were included in the pioglitazone and non-pioglitazone groups. Compared with patients who did not receive pioglitazone, those administered pioglitazone had a lower risk of developing ischemic stroke (adjusted hazard ratio: 0.78; 95% confidence interval: 0.62\u20130.95). The subgroup analyses defined by different baseline features did not reveal significant alterations in the observed effect of pioglitazone. Moreover, a significant decreasing trend in ischemic stroke risk with an increase in pioglitazone dose (p-value for trend\u2009=\u20090.04) was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pioglitazone use decreased the risk of new-onset ischemic stroke in Asian patients with type 2 DM and CV risk factors.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration number<\/jats:italic>\n                      CMUH104-REC2-115-CR4\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-020-01056-x","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T09:02:17Z","timestamp":1592643737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-7779","authenticated-orcid":false,"given":"Yi-Chih","family":"Hung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Ting","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-8656","authenticated-orcid":false,"given":"Da-Tian","family":"Bau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"1056_CR1","first-page":"439","volume":"18","author":"GBD 2016 Stroke Collaborators","year":"2016","unstructured":"GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2016;18:439\u201358.","journal-title":"Lancet Neurol"},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5853\/jos.2014.16.2.59","volume":"16","author":"FI Hsieh","year":"2014","unstructured":"Hsieh FI, Chiou HY. Stroke: morbidity, risk factors, and care in Taiwan. J Stroke. 2014;16:59\u201364.","journal-title":"J Stroke."},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105\u201313.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"957248","DOI":"10.1155\/2015\/957248","volume":"2015","author":"MJ Perez","year":"2015","unstructured":"Perez MJ, Quintanilla RA. Therapeutic actions of the thiazolidinediones in Alzheimer\u2019s disease. PPAR Res. 2015;2015:957248.","journal-title":"PPAR Res."},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/01.ATV.0000015598.86369.04","volume":"22","author":"O Barbier","year":"2002","unstructured":"Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717\u201326.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/01.ATV.0000124890.40436.77","volume":"24","author":"JS Sidhu","year":"2004","unstructured":"Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","volume":"111","author":"MR Langenfeld","year":"2005","unstructured":"Langenfeld MR, Forst T, Hohberg C, Kann P, L\u00fcbben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111:2525\u201331.","journal-title":"Circulation"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, PROactive Investigators, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial Inmacro Vascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389.","journal-title":"Lancet"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R Wilcox","year":"2007","unstructured":"Wilcox R, Bousser M-G, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone Clinical Trial Inmacro Vascular Events 04). Stroke. 2007;38:865\u201373.","journal-title":"Stroke"},{"key":"1056_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321\u201331.","journal-title":"N Engl J Med"},{"key":"1056_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.5551\/jat.30007","volume":"22","author":"R Tanaka","year":"2015","unstructured":"Tanaka R, Yamashiro K, Okuma Y, Shimura H, Nakamura S, Ueno Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT study. J Atheroscler Thromb. 2015;22:1305\u201316.","journal-title":"J Atheroscler Thromb."},{"key":"1056_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee M, Saver JL, Liao H-W, Lin C-H, Ovbiagele B. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke. 2017;48:388\u201393.","journal-title":"Stroke"},{"key":"1056_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamaneurol.2018.4406","volume":"76","author":"L Pantoni","year":"2019","unstructured":"Pantoni L. Potential new horizons for the prevention of cerebrovascular diseases and dementia. JAMA Neurol. 2019;76:521\u20132.","journal-title":"JAMA Neurol."},{"key":"1056_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-019-0874-5","volume":"18","author":"MH Woo","year":"2019","unstructured":"Woo MH, Lee HS, Kim J. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study. Cardiovasc Diabetol. 2019;18:67.","journal-title":"Cardiovasc Diabetol."},{"key":"1056_CR15","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/dom.13344","volume":"20","author":"CL Morgan","year":"2018","unstructured":"Morgan CL, Inzucchi SE, Puelles J, Jenkins-Jones S, Currie CJ. Impact of treatment with pioglitazone on stroke outcomes: a real-world database analysis. Diabetes Obes Metab. 2018;20:2140\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1056_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/1753-0407.12894","volume":"11","author":"S Miao","year":"2019","unstructured":"Miao S, Dong X, Zhang X, Jing S, Zhang X, Xu T, et al. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes. J Diabetes. 2019;11:684\u20139.","journal-title":"J Diabetes."},{"key":"1056_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-019-0979-x","volume":"19","author":"CH Liu","year":"2020","unstructured":"Liu CH, Lee TH, Lin YS, Sung PS, Wei YC, Li YR. Pioglitazone and PPAR-\u03b3 modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. Cardiovasc Diabetol. 2020;19:2.","journal-title":"Cardiovasc Diabetol."},{"key":"1056_CR18","doi-asserted-by":"publisher","first-page":"dgz026","DOI":"10.1210\/clinem\/dgz026","volume":"105","author":"FS Yen","year":"2020","unstructured":"Yen FS, Wang HC, Pan CW, Wei JC, Hsu CC, Hwu CM. Pioglitazone exposure reduced the risk of all-cause mortality in insulin-treated patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2020;105:dgz026.","journal-title":"J Clin Endocrinol Metab"},{"key":"1056_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","volume":"16","author":"M de Jong","year":"2017","unstructured":"de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease A meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2017;16:134.","journal-title":"Cardiovasc Diabetol."},{"key":"1056_CR20","unstructured":"Bureau of National Health Insurance. National Health Insurance Research Database. Taiwan. Zhunan, Taiwan. Bureau of National Health Insurance, Department of Health. http:\/\/nhird.nhri.org.tw\/en\/index.html. Accessed 2015."},{"key":"1056_CR21","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D\u2019Agostino RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572\u201381.","journal-title":"JAMA"},{"key":"1056_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"O Vaccaro","year":"2017","unstructured":"Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato, Maggioni AP, Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group, Italian Diabetes Society, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887\u201397.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1056_CR23","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2019-00361","volume":"104","author":"O Vaccaro","year":"2019","unstructured":"Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, TOSCA.IT Investigators, et al. Cardiovascular effects of pioglitazone or sulfonylureas according to pretreatment risk: moving toward personalized care. J Clin Endocrinol Metab. 2019;104:3296\u2013302.","journal-title":"J Clin Endocrinol Metab"},{"key":"1056_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-018-0663-6","volume":"17","author":"CW Chan","year":"2018","unstructured":"Chan CW, Yu CL, Lin JC, Hsieh YC, Lin CC, Hung CY, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018;17:20.","journal-title":"Cardiovasc Diabetol."},{"key":"1056_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000353679","volume":"36","author":"CJ Lu","year":"2013","unstructured":"Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis. 2013;36:145\u201351.","journal-title":"Cerebrovasc Dis."},{"key":"1056_CR26","first-page":"dgz252","volume":"105","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2019;105:dgz252.","journal-title":"J Clin Endocrinol Metab"},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamaneurol.2019.0079","volume":"76","author":"JD Spence","year":"2019","unstructured":"Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol. 2019;76:526\u201335.","journal-title":"JAMA Neurol."},{"key":"1056_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.12652","volume":"18","author":"RA DeFronzo","year":"2016","unstructured":"DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes Obes Metab. 2016;18:454\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"1056_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2337\/dc18-0588","volume":"41","author":"MJB Van Baar","year":"2018","unstructured":"Van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 Inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41:1543\u201356.","journal-title":"Diabetes Care"},{"key":"1056_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.JE20140076","volume":"24","author":"CL Cheng","year":"2014","unstructured":"Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol. 2014;24:500\u20137.","journal-title":"J Epidemiol."},{"key":"1056_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"CL Cheng","year":"2015","unstructured":"Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol. 2015;201:96\u2013101.","journal-title":"Int J Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01056-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T19:09:04Z","timestamp":1624129744000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01056-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01056-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17243\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-17243\/v2","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Review Board of China Medical University (CMUH104-REC2-115-CR4). Owing to the retrospective nature of the study, informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}